化学放射線療法
A Randomized Controlled Trial of Stereotactic Body Radiation Therapy Versus Chemoradiation Following Induction Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer.Thakur V, Khosla D, Singh G, et al. J Gastrointest …
Clinical predictors of pseudoprogression in glioblastoma: a retrospective cohort analysis.Hoosemans LJN, Panayotopoulos LF, van Kuijk SMJ, et al. J Neurooncol. 2025 Oct 24;176(1):42. doi: 10.1007/s11060-025-05299-0. PMID: 41134378; PMCID: …
Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study. Ahn MJ, Lin SH, Yang CT, et al.…
Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial.Borel C, Sun XS, Coutte A, et al. Radiother Oncol. 2024 Aug;197:11…
Development and validation of predictive model for emesis in cervical cancer patients receiving concurrent chemoradiotherapy based on multi-institutional retrospective study.Yoshida K, Morita H, Nakai M, et al. Sci Rep. 2025 Oct 27;15(1):3…
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.Lu S, Kato T, Dong X, et al. N Engl J Med. 2024 Aug 15;391(7):585-597. doi: 10.1056/NEJMoa2402614. Epub 2024 Jun 2. PMID: 38828946. 【概要】・化学放射線療法語の切除不能 EG…
Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA stud…
Locally advanced non-small cell lung cancer with negative or low programmed death ligand 1 expression: a prognostic factor analysis of real-world data after the PACIFIC trialKashihara T, Nakayama Y, Okuma K, et al.. Radiat Oncol. 2025 Oct …
A Phase II Exploratory Trial Evaluating CT-based Mid-Treatment Nodal Response to Select for De-escalated chemoradiation therapy in the definitive management of p16+ Oropharyngeal Cancer.Kim JK, Tam M, Kim SG, et al. Int J Radiat Oncol Biol…
Consolidative nivolumab versus observation in unresectable stage III non-small cell lung cancer patients following neoadjuvant nivolumab plus chemotherapy and concurrent chemoradiotherapy (CA209-7AL): a randomized clinical trial.Qiu B, Zha…
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial.Peters S, Pujol JL, Dafni U, et al. Ann Oncol.…
CheckMate 73L: Phase III study comparing nivolumab (N) + concurrent chemoradiotherapy (CCRT) followed by N ± ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage (stg) III NSCLChttps://www.esmoi…
Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 StudyBradley JD, Sugawara S, Lee KH, et al. J Clin Oncol. 2025 Oct 13:JCO2500036. doi: 10.1200/JCO-2…
Trends and efficacy of definitive radiotherapy regimens for locally advanced head and neck cancer in elderly patients: A population-based analysis by the German cancer registry group.Tinhofer I, Hofmann E, Trelinska-Finger A, et al. Eur J …
Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2 https://www.esmoopen.com/article/S2059-7029(24)00754-3/pdf 【概要】・PACIFIC-2試験は同時化学放射線療法＋デュルバ…
Concurrent Chemoradiation ± Atezolizumab (atezo) in Limited-Stage Small Cell Lung Cancer (LS-SCLC): Results of NRG Oncology/Alliance LU005 https://www.redjournal.org/article/S0360-3016(24)03238-3/fulltext 【概要】・NRG-LU005第III相試験（第…
Chemoradiotherapy versus radiotherapy in patients with stage T1-2N0M0 small cell lung cancer: a retrospective cohort study.Lin J, Liang HW, Liu Y, et al. BMC Pulm Med. 2025 Sep 30;25(1):435. doi: 10.1186/s12890-025-03918-0. PMID: 41029302.…
Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma: The DIAMOND Randomized Clinical Trial.DIAMOND Study Group. JAMA. 2025 Sep 16;334(11):973-983. doi: 10.1001/jama.2025.13205. PMID: 40839372; PMCID: P…
Treatment outcomes of definitive radiotherapy for unresectable salivary gland cancers: a multicenter, retrospective study in northern Japan.Ohkoshi A, Ishii R, Higashi K, et al. Jpn J Clin Oncol. 2025 Sep 22:hyaf147. doi: 10.1093/jjco/hyaf…
Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited-Stage Small-Cell Lung Cancer in the Phase 3 ADRIATIC Trial.Zenke Y, Shiraishi Y, Goto Y, et al. Cancer Sci. 2025 Sep 21. doi: 10.1111/cas.70188. Epub ahead of p…
Three-Dimensional Conformal Radiotherapy Versus Image-Guided Intensity Modulated External Beam Radiotherapy in Locally Advanced Cervical Cancer: A Phase III Randomized Control Study.Rai B, Dey T, Ballari N, et al. Clin Oncol (R Coll Radiol…
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.Cheng Y, Spigel DR, Cho BC, et al. N Engl J Med. 2024 Oct 10;391(14):1313-1327. doi: 10.1056/NEJMoa2404873. Epub 2024 Sep 13. PMID: 39268857. 【概要】・化学放射線療…
Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Stage III Non-Small C…
Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial.McCormack M, …
Neoadjuvant chemoradiation with camrelizumab and nimotuzumab for initially inoperable esophageal squamous cell carcinoma: A single-arm phase 2 trial.He Y, Liu H, Li X, et al. Eur J Cancer. 2025 Aug 15;228:115717. doi: 10.1016/j.ejca.2025.1…
Induction chemotherapy plus chemoradiotherapy in esophageal cancer: long-term results and exploratory analyses of a randomized controlled trial. Liu S, Chen B, Zhu Y, et al. Oncologist. 2025 Jul 4;30(7):oyae295. doi: 10.1093/oncolo/oyae295…
Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial.Mayadev J, Zamarin D, Deng W, et al. Nat Commun. 2025 Jan 9;16(1):553. doi: 10.1038/s41467-024-55200-2. PMID: 39788…
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. Herbst RS, Majem M, Barlesi F, et al. J Clin …
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study.Bourhis J, Licitra LF, Burtness B, et al. J Clin Oncol. 2025 S…
Randomized Evaluation of the PET-Adjusted IMRT for NSCLC Trial (REPAINT).Ohri N, Bodner WR, Kabarriti R, et al. Int J Radiat Oncol Biol Phys. 2025 Jun 1;122(2):365-373. doi: 10.1016/j.ijrobp.2025.01.005. Epub 2025 Jan 23. PMID: 39862898. …
